Biotricity (BTCY)
(Delayed Data from OTC)
$0.49 USD
+0.04 (8.21%)
Updated Aug 6, 2025 03:54 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BTCY 0.49 +0.04(8.21%)
Will BTCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BTCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTCY
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
BTCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BTCY
Biotricity Inc (BTCY) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Q4 2025 Biotricity Inc Earnings Call Transcript
Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin ...
Biotricity reports FY25 EPS (56c) vs. ($1.66) last year